NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Astria Therapeutics, Inc. (ATXS) Stock Analysis

Astria Therapeutics, Inc. (ATXS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ATXS

$12.58

$0.00 (0.00%)

Last trade January 23, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATXS with… →

ATXS Key Statistics

As of Jan 23, 2026
Trading
Open
$12.58
Previous Close
$12.58
52-Week Range
3.56–13.29
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.02
Valuation
Market Cap
$718.13M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1017.18
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.14
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+66.62%
Dividend and dates
Avg Volume
1.09M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ATXS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−3.90%
2025+46.42%
2024 (partial year)−5.40%

As of January 23, 2026.

ATXS Valuation vs Biotechnology Median

Median of 656 stocks
MetricATXSBiotechnology medianvs median
P/S ratio1017.1815.2666.6x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Astria Therapeutics, Inc. (ATXS) carries a market capitalisation of $718.13M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 78.

The most recent close on file for ATXS is $12.58, dated January 23, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $3.56 to $13.29. The latest close sits 253.87% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $706.00K. The reported profit margin is 0%. Trailing earnings per share are −2.14.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 1,017.18 times revenue. On price-to-sales that is 66.6 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.02. Annualized volatility over the trailing 1 year is 72.84%. The trailing one-year price return is +66.62%.

Growth & Income

The record shows no dividend for ATXS.

So far in 2026 the price is −3.90%. The record holds one complete calendar year, 2025, which returned +46.42%.

Peer Comparison

Astria Therapeutics, Inc. (ATXS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Astria Therapeutics, Inc. ATXS $718.13M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Astria Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of January 23, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Astria Therapeutics, Inc.

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.

Visit website →